NovoRapid
An injectable fast-acting insulin analogue used to control high blood sugar in patients with diabetes.
Where Insulin Aspart is approved
All regulators →Of the three regulators tracked here, the first to approve Insulin Aspart was the EU, on 7 Sep 1999. It is approved in 3 of the 3 regulators tracked here.
- 3 FDA-approved biosimilars, 2 interchangeable: Garzulys, Kirsty, Merilog
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Insulin Aspart
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Insulin Aspart works
All drug targets →- Insulin receptor agonist AgonistTarget: INSR insulin receptorChEMBL only
- Burkitt lymphomaPhase 3
- Acute lymphoblastic leukemiaPhase 3
- Cirrhosis of liverPhase 3
- Cystic fibrosis-related diabetesPhase 3
- Gestational diabetesPhase 3
- Lymphoblastic lymphomaPhase 3
- Type 1 diabetes mellitusPhase 3
- Type 2 diabetes mellitusPhase 3
- HypoglycemiaPhase 2/3
- Mental deteriorationPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201496, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Insulin Aspart
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 16 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Fiasp, NovoMix, NovoRapid, Dazparda (biosimilar), Insulin aspart Sanofi (biosimilar), Kirsty (previously Kixelle) (biosimilar)EMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Insulin Aspart
- ChEMBL
- CHEMBL1201496
- PubChem CID
- 168324416
- CAS number
- 116094-23-6
- Wikidata
- Q2754775
- Wikipedia
- Insulin aspart
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
What NovoRapid is used for
Insulin Aspart (NovoRapid / NovoLog) is an injectable fast-acting insulin analogue used to control high blood sugar in patients with diabetes. It belongs to the Rapid-acting insulin class.
Related clinical trials recruiting now
Compare NovoRapid with
Explore more
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 9 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.